In:
Cardiovascular Therapeutics, Wiley, Vol. 31, No. 4 ( 2013-08), p. 193-200
Abstract:
Polymer‐free sirolimus‐ and probucol‐eluting stents ( R eal D ual drug‐eluting stents [ DES ]) is as effective as first‐generation DES in treating coronary artery stenosis. It is unknown whether sirolimus‐eluting stents containing biodegradable polymer ( E xcel) would be superior to real D ual DES . This study aimed to investigate the difference in target vessel revascularization ( TVR ) at 12 months in patients with coronary artery disease treated by the implantation of D ual D ES or Excel stents. Methods Three hundred and forty‐six patients with de novo coronary artery disease were recruited from six centers in China and randomly assigned to either the D ual D ES or the Excel group. The primary endpoint was the occurrence of TVR at 12 months. The secondary endpoint was angiographic in‐stent restenosis and late lumen loss at 13 months. Stent thrombosis ( ST ) served as the safety endpoint. Dual anti‐platelet therapy ( DAPT ) was prescribed for 6 months. Results Clinical follow‐up for 12 months and repeat angiography at 13 months were available in 100% and 〉 90% of patients, respectively. The ISR and in‐stent late loss were significantly different between the E xcel (3.1%, 0.09 ± 0.11 mm) and the D ual D ES (19.5%, 0.36 ± 0.32 mm, P 〈 0.001, P 〈 0.001, respectively) groups. The TVR (3.5%) in the E xcel group was significantly less than in the D ual D ES group (13.9%, P = 0.001). The ST rate beyond 12 months in the D ual D ES group was 0%, and this was 1.2% in the E xcel group ( P = 0.499). Conclusions The E xcel stent was statistically superior to the D ual D ES in terms of restenosis, late loss, and TVR for long lesions.
Type of Medium:
Online Resource
ISSN:
1755-5914
,
1755-5922
DOI:
10.1111/cdr.2013.31.issue-4
DOI:
10.1111/j.1755-5922.2012.00319.x
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
2417088-4
Permalink